Table 2.
Statistical significance of variables used in disease state definition (i.e., clinical assessments) and action (medications).
| Time | Variables | Coef | p-value |
|---|---|---|---|
| (Variables used in disease state definition) | |||
| Hoehn and Yahr | 0.8967 | 0 | |
| Age | 0.0864 | 0 | |
| Total MoCA | − 0.0534 | 0.01 | |
| Total UPDRS III scores | 0.7816 | 0 | |
| % change of total UPDRS scores | − 0.0246 | 0 | |
| Subtype AR (vs. mixed type) | 1.5576 | 0 | |
| Subtype TD (vs. mixed type) | 0.6056 | 0.213 | |
| Levodopa | 5.5486 | 0 | |
| Dopamine agonist | 4.5439 | 0 | |
| Other medicine | 2.2017 | 0 | |
| Levodopa + Other medicine | 5.942 | 0 | |
| Levodopa + Dopamine agonist | 5.5351 | 0 | |
| Dopamine agonist + Other medicine | 3.8986 | 0 | |
| Levodopa + Dopamine agonist + Other medicine | 6.1054 | 0 | |
| (Variables used in actions) | |||
| Levodopa | − 6.9801 | 0 | |
| Dopamine agonist | − 5.0293 | 0 | |
| Other medicine | − 0.825 | 0.094 | |
| Levodopa + other medicine | − 6.9232 | 0 | |
| Levodopa + Dopamine agonist | − 7.2501 | 0 | |
| Dopamine agonist + other medicine | − 5.1182 | 0 | |
| Levodopa + Dopamine agonist + other medicine | − 8.5083 | 0 | |
| (Outcome) total UPDRS III scores |
We fitted prediction model as total UPDRS scores at (penalty) ~ variables at (used in disease state) + variables at (actions) using multivariate regression (i.e., generalized least square) and selected variables that are statistically significant on total UPDRS scores on the next timestep (). Note that the % change of total UPDRS scores are 100% (Total UPDRS scores at − Total UPDRS scores at )/Total UPDRS scores at . AR = Akinetic-rigid, TD = tremor-dominant.